Moringa seed extract containing 1-O-(4-hydroxy-methylphenyl)-α-l-rhamno-pyranoside (GR) has been reported to ameliorate CCl4 induced hyperlipidemia in the liver. However, it is unclear whether GR has any therapeutic effect on NAFLD. This study aimed to determine the hypolipidemic and concomitant hepatoprotective potential of GR. The structure and purity of GR were assessed and characterized using high performance liquid chromatography-mass spectrometry (UPLC-MS/MS). The NAFLD model was established based on the L02 cells in vitro. After GR intervention, intracellular fat deposition and reactive oxygen content were significantly reduced, GR could up-regulation of AMPK and PPARα and the down-regulation of mTOR and SREBP-1, which play a key role in liver lipid homeostasis. In vivo experiments revealed that GR intervention significantly decreased serum fat content, inhibited liver injury, and increased antioxidant mechanism in mice fed with high fat diet. Hence, GR demonstrated promising hypolipidemic and hepatoprotective activities, serving as a potential candidate for NAFLD therapy.
Keywords: AMPK/mTOR/SREBP-1 pathway; Gastrodigenin rhamno-pyranoside (GR); Hypolipidemic; Moringa oleifera seeds; Non-alcoholic fatty liver disease (NAFLD).
Copyright © 2022 Elsevier Ltd. All rights reserved.